Blanket Purchase Agreement V797P2140D-36C25018A0002

Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc., holds a $225,000 Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract with the General Services Administration (GSA). Under this multiple award IDIQ contract, Amicus Therapeutics US, LLC has been awarded various delivery orders by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to provide the pharmaceutical product Galafold (migalastat) to support healthcare services for...

Alexion Pharmaceuticals Inc., a Boston, Massachusetts-based biopharmaceutical company specializing in rare disease therapeutics, was awarded a multiple-award Federal Supply Schedule contract under the Pharmaceuticals and Drugs General Services Administration Schedule (FSS-61-IB) by Veterans Integrated Service Network 12 on April 1, 2018, with a ceiling value of $47 million and completion date of September 30, 2026. The contract encompasses the supply of specialized pharmaceutical products,...

This Federal Supply Schedule (FSS) contract, awarded by the Veterans Integrated Service Network 12 (VISN 12) of the Department of Veterans Affairs, provides Pharmaceuticals and Drugs (FSS-61-IB) to government agencies. The prime contractor, Greenstone LLC, is a global healthcare company that has been supplying a wide range of medications and medical products, including corticosteroids, cardiovascular drugs, antibiotics, antifungals, and gastrointestinal medications, to support the medical...

Astellas Pharma US, Inc. was awarded a single-award Blanket Purchase Agreement by the Veterans Health Administration's National Acquisition Center on October 7, 2021, for the supply of two oncology pharmaceuticals: XTANDI (enzalutamide) and XOSPATA (gilteritinib). Established against the existing Pharmaceuticals and Drugs Federal Supply Schedule contract, this BPA carries a ceiling value of $296,500 and extends through October 6, 2026. The agreement serves to facilitate efficient procurement...

Agios Pharmaceuticals, Inc. (UEI: KKWAB4MN58M3) was awarded a multiple award Federal Supply Schedule contract on September 29, 2025, to provide drugs, pharmaceuticals, and hematology-related products under General Services Administration (GSA) Federal Supply Schedule category 65 I B. The contract carries a ceiling value of $225,000 and extends through September 28, 2030, with no set-aside restrictions applied to this award. The contract incorporates 2026 Public Law pricing updates and is...

Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc., holds a multiple-award Federal Supply Schedule contract (FSS-61-IB) for Pharmaceuticals and Drugs with the Department of Veterans Affairs, valued at $13,024,630 and effective through August 31, 2029. The contract was awarded on September 1, 2024, without set-aside restrictions, and serves as the parent indefinite delivery vehicle enabling various Veterans Integrated Service Networks (VISNs) to place task orders for...

The Department of Veterans Affairs (VA) has awarded multiple firm fixed price delivery order contracts to Amylyx Pharmaceuticals Inc., a self-certified small disadvantaged business, for the provision of RELYVRIO, Amylyx's pharmaceutical product containing sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis (ALS). These delivery orders, valued at over $3 million in aggregate, were placed against Amylyx's existing federal contract vehicles, including a...

Golden State Medical Supply, Inc. was awarded a single-award Indefinite Delivery Contract by the Department of Veterans Affairs (VA) National Acquisition Center on November 17, 2021, to supply mesalamine tablets at a ceiling value of $83.9 million through November 16, 2026. The contract encompasses a one-year base period from November 17, 2021 to November 16, 2022, with four optional one-year renewal periods. The solicitation, posted as a pre-solicitation notice on June 3, 2021, specified the...

Golden State Medical Supply, Inc. was awarded a single-award Indefinite Delivery Contract by the Department of Veterans Affairs National Acquisition Center to provide mycophenolic acid tablets. The contract has a base year and four one-year options with a potential value of $19,275,127.05 and a period of performance through April 2024. As the prime contractor, Golden State Medical Supply will leverage its distribution infrastructure to supply mycophenolic acid tablets and other pharmaceutical...

Genzyme Corporation, doing business as Sanofi Genzyme, holds a $659.7 million multiple-award Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB) awarded by the Veterans Integrated Service Network 12 on May 15, 2019, with an ultimate completion date of April 30, 2026. This indefinite delivery vehicle enables the Department of Veterans Affairs Veterans Health Administration to procure a broad range of specialty pharmaceutical products to support treatment programs for veterans...